Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study
Frontiers in Oncology · 26.06.2026 · 16
DOI: 10.3389/fonc.2026.1852055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 26.06.2026. Verfasst von Zhenghua Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Breast Disease Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health Commission of the People's Republic of China.
Abstract (Originalsprache)
Purpose
To compare the effectiveness, safety, and tolerability of adjuvant trastuzumab plus pertuzumab (HP) versus trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with residual invasive disease after neoadjuvant therapy, and to perform exploratory analyses of outcomes in clinically favorable subgroups. Materials and methods Patients with HER2-positive breast cancer and residual invasive disease after NAT, enrolled between 2020 and 2024, were included. Propensity score matching (1:1) was applied to adjust for baseline characteristic differences. Kaplan-Meier survival analysis and Cox proportional hazards models were used to compare survival outcomes (iDFS, RFS, OS) between the two groups. Additionally, the incidence of adverse events and treatment adherence were compared.
Results
A total of 272 patients were analyzed, with 134 remaining after propensity score matching. After a median follow-up of 37.7 months, no statistically significant differences in short-term survival outcomes were detected between the two groups. Grade 3 or higher adverse events occurred more frequently in the T-DM1 group, particularly thrombocytopenia. Treatment interruption or regimen modification occurred in 22.7% of patients in the T-DM1 group and 2.2% in the HP group.
Conclusion
In HER2-positive breast cancer patients with residual invasive disease after NAT, no statistically significant difference in short-term recurrence or survival outcomes was detected between adjuvant HP and T-DM1, while HP was associated with a more favorable safety and tolerability profile. These findings should be interpreted as complementary real-world evidence in the contemporary dual-blockade era and as hypothesis-generating support for future risk-adapted adjuvant strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Breast Disease Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Hebei Medical University, Shijiazhuang, Hebei, China.
Förderung
- National Health Commission of the People's Republic of China
Zitieren
APA
Liu, Z., Wang, X., Gai, J., Wang, C., Yi, X., Liu, Y., & Zhou, T. (2026). Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1852055
Vancouver
Liu Z, Wang X, Gai J, Wang C, Yi X, Liu Y, et al. Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1852055
BibTeX
@article{Liu2026,
author = {Liu, Zhenghua and Wang, Xinyu and Gai, Jiayan and Wang, Chen and Yi, Xinlu and Liu, Yufei and Zhou, Tao},
title = {Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1852055}
}
EUVIMED